

FORM PTO-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Sheet 1 of 4

ATTORNEY DOCKET NO.	SERIAL NO.
3078/4/US 31104/USA (6794-000094/COC)	10/016,146
APPLICANT	
Cunningham, et al.	
FILING DATE	GROUP
December 10, 2001	1614

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.	PS	4,677,111	6/30/87	Haga, et al.	514/274	
2.	PS	5,256,812	10/26/93	Alig, et al.	560/035	
3.	PS	5,518,732	5/21/96	Nigam	424/427	
4.	PS	5,753,230	5/19/98	Brooks	424/158.1	
5.	PS	5,766,591	6/16/98	Brooks	424/184.1	
6.	PS	6,013,651	1/11/00	Rogers	514/269	

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes No
7.	PS	AU-A-79090/94	6/8/95	Australia	—	
8.	PS	AU-A-57984/94	10/6/94	Australia	—	
9.	PS	2,059,857	7/25/92	Canada	—	
10.	PS	2,134,418	4/29/95	Canada	—	
11.	PS	EP 0 343 893 A1	11/29/89	EPO	—	
12.	PS	EP 0 343 894 A1	11/29/89	EPO	—	
13.	PS	EP 0 478 328 A1	4/1/92	EPO	—	
14.	PS	EP 0 478 363 A2	4/1/92	EPO	—	
15.	PS	DE 43 38 944 A1	5/18/95	Germany	—	X
16.	PS	WO 95/32710	12/7/95	PCT	—	
17.	PS	WO 98/31359	7/23/98	PCT	—	
18.	PS	WO 95/28426	10/26/95	PCT	—	

Examiner:


Phyllis Spivack

Date Considered:

6/20/05

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EV 726255925 US



FORM PTO-1449 (Based on Form PTO-1449)		ATTORNEY DOCKET NO.	SERIAL NO.
		30784/US 31104/USA (6794-000094/COC)	10/016,146
		APPLICANT	
		Cunningham, et al.	
		FILING DATE	GROUP
Sheet 2 of 4		December 10, 2001	1614

FOREIGN PATENT DOCUMENTS


Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/Subclass	Translation Yes	No
19.	PS	WO 95/14714	6/1/95	PCT			
20.	PS	WO 98/14192	4/9/98	PCT			
21.	PS	WO 93/08823	5/13/93	PCT			
22.	PS	WO 97/08145	3/6/97	PCT			
23.	PS	WO 96/00730	1/11/96	PCT			
24.	PS	WO 96/00574	1/11/96	PCT			
25.	PS	94/9017	11/14/94	South Africa			
26.	PS	94/2124	3/25/94	South Africa			
27.	PS	94/0435	1/21/94	South Africa			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
28.	PS	Adamis, et al., Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes with Proliferative Diabetic Retinopathy, American Journal of Ophthalmology, Vol. 118 (1994) 445-450 .
29.	PS	Brooks, et al., Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Antiogenic Blood Vessels, Cell, Vol. 79 (1994) 1157-1164.
30.	PS	Brooks, et al., Requirement for Vascular Integrin $\alpha_v\beta_3$ for Angiogenesis, Science, Vol. 264 (1994) 569-571.
31.	PS	Carter, et al., Chemotherapy of Cancer, Sec. Ed., John Wiley & Sons, NY, NY (1981) 107-108.
32.	PS	Choi, et al., Inhibition of Neointimal Hyperplasia by Blocking $\alpha_v\beta_3$ Integrin with a Small Peptide Antagonist Gp6GRDSPCA, Journal of Vascular Surgery, Vol. 19 (1) 125-134

Examiner: Phyllis Spivack Date Considered: 6/20/05

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




FORM HDP-4 (Based on Form PTO-1449)		ATTORNEY DOCKET NO.	SERIAL NO.
		3078/4/US 31104/USA (6794-000094/COC)	10/016,146
		APPLICANT	
		Cunningham, et al.	
		FILING DATE	GROUP
		December 10, 2001	1614
Sheet 3 of 4			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	Document Description
33.	PS	Clyman, et al., β_1 and β_3 Integrins Have Different Roles in the Adhesion and Migration of Vascular Smooth Muscle Cells on Extracellular Matrix, Experimental Cell Research, Vol. 200, (1992) 272-284.
34.	PS	Fields, Integrins: Cell Adhesion Molecules in Cancer, Exp. Opin. Ther. Patents, Vol. 8 (No. 6), (1998) 633-644.
35.	PS	Hong, et al., Discovery of HIV-1 Integrase Inhibitors by Pharmacophore Searching, J. Med. Chem., American Chemical Society, v. 40 (1997) 930-936.
36.	PS	Liaw, et al., The Adhesive and Migratory Effects of Osteopontin Are Mediated Via Distinct Cell Surface Integrins: Role of a $\alpha_v\beta_3$ in Smooth Muscle Migration to Osteopontin in Vitro, Journal of Clinical Investigation, Vol. 95 (1995) 713-724.
37.	PS	Derwent Abstract 1987-009150/198702.
38.	PS	Derwent Abstract 1987-065042/198710.
39.	PS	Derwent Abstract 1989-055466/198908.
40.	PS	Derwent Abstract 1989-349934/198948.
41.	PS	Derwent Abstract 1992-398070/199248.
42.	PS	Derwent Abstract 1993-060253/199308.
43.	PS	Derwent Abstract 1993-127579/199316.
44.	PS	Nicklaus, et al., HIV-1 Integrase Pharmacophore: Discovery of Inhibitors Through Three-Dimensional Database Searching, J. Med. Chem. v. 40 (1997) 920-929.
45.	PS	Peacock, et al., Angiogenesis Inhibition Suppresses Collagen Arthritis, Journal of Experimental Medicine, Vol. 175 (1992) 1135-1138.
46.	PS	Pommier, et al., HIV-1 Integrase as Target for Antiviral Drugs, Antiviral Chemistry & Chemotherapy, Vol. 8 (No. 6) (1997) 463-483.
47.	PS	Schnur, et al., N-(5-Fluorobenzothiadaol-2-yl)-2-guanidinothiazone-4-carboxamide. A Novel, Systematically Active Antitumor Agent Effective Against 3LL Lewis Lung Carcinoma, Journal of Medicinal Chemistry, Vol. 34 (3) (1991) 914-918.

Examiner: Playlis Spivack Date Considered: 6/20/05

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM HDI-1440 (based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Sheet 4 of 4

ATTORNEY DOCKET NO.	SERIAL NO.
30784/US 31104/USA (6794-000094/COC)	10/016,146
APPLICANT	
Cunningham, et al.	
FILING DATE	GROUP
December 10, 2001	1614

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
48.	PS	Schnur, et al., Quantitative Structure-Activity Relationships of Antitumor Guanidinothiazolecarboxamides with Survival Enhancement for Therapy in the 3LL Lewis Lung Carcinoma Model, Journal of Medicinal Chemistry, Vol. 34 (7) (1991) 1975-1982
49.	PS	Seftor, et al., Role of the $\alpha_v\beta_3$ Integrin in Human Melanoma Cell Invasion, Proceedings of the National Academy of Sciences U.S.A., Vol. 89 (1992) 1557-1561 .
50.	PS	Smith, et al., Interactions of Integrins $\alpha_v\beta_3$ and GlycoProtein IIb-IIIa with Fibrinogen, Journal of Medicinal Chemistry, Vol. 265 (21) (1990) 12267-12271.
51.	PS	White, Integrins as Virus Receptors, Current Biology, Vol. 3 (9) (1993) 596-599 .
52.	PS	Yue, Osteopontin-Stimulated Vascular Smooth Muscle Cell Migration is Mediated by $\alpha_v\beta_3$ Integrin, Experimental Cell Research, Vol. 214 (1994) 459-464 .

Examiner:

Phyllis Spivack

Date Considered:

1/20/05

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.